BRIEF: Xuanzhu Biopharma launches IPO to raise $100 million
Xuanzhu Biopharmaceutical Co., Ltd. (2575.HK), spun off from Sihuan Pharma (0460.HK), launched its IPO on Monday, aiming to sell 67.3 million shares for HK$11.60 each to raise HK$780 million ($100…
BRIEF: Baiyunshan invests $105 million for 11% of NanJing Pharma
Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. (0874.HK; 600332.SH) said on Sunday it paid 749 million yuan ($105 million) via its Guangzhou GP Fund II subsidiary for 11.04% of NanJing Pharmaceutical…
BRIEF: CF PharmTech to raise $77 million in Hong Kong IPO
Pharmaceutical manufacturer CF PharmTech Inc. (2652.HK) on Friday launched its Hong Kong IPO, seeking to raise about HK$601 million ($77 million) by selling 41.2 million shares for HK$14.75 apiece. The…
BRIEF: 111 Inc.’s revenue drops in second quarter
Drug seller 111 Inc. (YI.US) said on Wednesday its revenue fell 6.4% year-on-year to 3.2 billion yuan ($450 million) in the second quarter, as revenue for its core business of…
Years of losses, thin profit margins leave 160 Health feeling down
After two earlier failures, the online healthcare platform’s IPO has been approved by the Hong Kong Stock Exchange Key Takeaways: 160 Health has been approved to list in Hong Kong,…
Baiyunshan serves up high dividend in lieu of vanilla results
Profits from the company’s Great Health segment rose 14% in the first half of 2025, primarily driven by strong results for its popular Wanglaoji herbal tea Key Takeaways: Baiyunshan’s revenue…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
Recent Articles
BRIEF: Baiyunshan invests $105 million for 11% of NanJing Pharma
0874.HK
600332.SHG
600713.SHG
Baiyunshan serves up high dividend in lieu of vanilla results
0874.HK
600332.SHG
